ArticlePakistan journal of medical sciences2026
Correlation of differential expression of MEG3 lnc-RNA with biochemical parameters in Type-II diabetic patients with and without diabetic kidney disease.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objectives: Diabetic kidney disease (DKD) is a complication of type-II diabetes mellitus (DM) leading to significant morbidity and mortality. Long non-coding RNAs (lnc-RNAs) are a class of ribonucleic acid that exert their effects in development of such complications through epigenetic modifications. The study was conducted with the objectives to compare the relative expression of MEG3 lnc-RNA in patients of Type-II DM, with and without DKD, and to determine the correlation of this expression with blood and urine biomarkers. Methodology: A cross-sectional study was conducted at the University of Health Sciences, Lahore, after ethical approval from December 2022 till October 2023. Study participants were recruited in three groups having DKD, Type-II DM and healthy individuals, each group having 68 participants. Analysis of blood and urine biomarkers was performed. MEG3 lnc-RNA expression was determined by using RT-PCR. Kruskal Wallis test, post hoc Mann-Whitney U test and Spearman's correlation were used for data analysis. Results: The relative expression of MEG3 lnc-RNA was significantly higher in the DKD group (median=3.83, IQR=1.22-3.83) as compared to the DM (median= 2.22, IQR= 0.49-3.12) and healthy groups (median= 1.97, IQR= 1.17-1.97) with a Conclusions: MEG3 lnc-RNA has a higher relative expression in the patients suffering from DKD in the local diabetic population. In future, it may be used as a diagnostic marker as well as for inducing epigenetic modification through RNA transfection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.